Tirzepatide in Sweden: licence and cost

In Sweden, tirzepatide is a prescription-only medicine sold under the brand name Mounjaro. It is legal, it is stocked by Swedish pharmacies, and it is licensed for two adult indications. What it is not is subsidised. Mounjaro sits outside the Swedish pharmaceutical benefits scheme, which means Swedish patients pay the full pharmacy price out of pocket. That single fact explains most of what people find confusing about tirzepatide in Sweden.

The licence: EMA central authorisation, valid in Sweden since 2022

Mounjaro holds a centrally authorised European marketing authorisation granted on 15 September 2022, with Eli Lilly Nederland B.V. as the marketing authorisation holder and ATC code A10BX16^[1]. Central authorisation means one approval covers every EU and EEA member state at once. Läkemedelsverket, the Swedish Medical Products Agency, does not run a separate national assessment of safety or efficacy for a centrally authorised medicine. It applies the EU label.

Two adult indications are live in Sweden. The first is type-2 diabetes that is insufficiently controlled, as monotherapy where metformin is unsuitable or as an add-on. The second is weight management in adults with obesity, or with overweight plus at least one weight-related condition. The summary of product characteristics was last updated on 26 February 2026^[1].

The most recent label movement is paediatric. On 11 December 2025 the EMA's Committee for Medicinal Products for Human Use recommended extending Mounjaro to adolescents and children from 10 years of age with type-2 diabetes that is not satisfactorily controlled, alongside diet and physical activity^[2]. Once the European Commission ratifies a CHMP opinion, the extension becomes part of the same centralised authorisation and applies in Sweden without any further Swedish step. Reimbursement is a different matter entirely, and it does not follow.

Mounjaro arrived in Swedish pharmacies in October 2024, unsubsidised

Eli Lilly launched Mounjaro in Sweden on 17 October 2024, initially in 2.5 mg and 5 mg pens, at roughly 2,700 kronor per month for the 5 mg maintenance dose. It was launched outside the läkemedelsförmån (the benefits scheme), with the company saying at the time that it was preparing a subsidy application but could not say when it would be filed^[3].

Uptake did not wait for the subsidy. Ylva Trolle Lagerros, senior physician at the obesity centre in Stockholm, told Läkartidningen shortly after launch that she had written several prescriptions per clinic day, and noted that the drug was cheaper than parallel-imported Wegovy and free of the supply problems that had dogged semaglutide^[4]. By November 2025, Mounjaro was the highest-selling medicine in Sweden measured by total pharmacy sales value, at 157.3 million kronor in a single month, all of it unsubsidised^[5].

Why the subsidy question is the real gatekeeper

Sweden separates licensing from payment. Läkemedelsverket handles the former by applying the EU authorisation. The Dental and Pharmaceutical Benefits Agency (TLV) handles the latter, deciding which medicines enter the högkostnadsskydd, the high-cost protection scheme that caps what a patient pays over a rolling twelve months. A medicine can be fully licensed and still sit entirely outside that cap. Tirzepatide currently does.

Sweden has been restrictive with this drug class for years. In March 2023, TLV clarified the subsidy limitation attached to seven GLP-1 receptor agonists then in the scheme, including Ozempic and Rybelsus, to make explicit that only patients with type-2 diabetes receive them subsidised^[6]. The weight-management use of the class has been kept outside the scheme rather than restricted within it, which is the same pattern described on our semaglutide in Sweden page.

February 2026 sharpened that position. TLV decided that Wegovy (semaglutide) should not be included in the high-cost protection scheme at all^[7]. The agency's reasoning is worth reading closely if you want to predict what happens to tirzepatide, because it was not primarily a clinical argument. TLV pointed to the roughly 1.6 million Swedes who meet the broad label criteria, the resulting budget impact and displacement of other care, the absence of any mechanism to verify that prescribing would stay inside a cost-effective group, and the failure of tripartite price negotiations between the manufacturer, the regions and TLV. For adolescents aged 12 to 18, TLV separately found the cost not justified by the evidence presented^[7].

Where the Mounjaro subsidy application stands

Eli Lilly applied to TLV for Mounjaro, with reporting placing the application as far back as November 2024, and TLV has had a separate assessment of tirzepatide running alongside the Wegovy case^[5][8]. As of July 2026 no TLV decision on Mounjaro appears in the agency's published medicines decision archive. The honest summary is that tirzepatide is pending, not rejected, and that the Wegovy reasoning gives the applicant a difficult set of objections to answer.

The practical consequence for a Swedish patient is unchanged either way in the short term. A licensed Swedish prescriber can write a Mounjaro prescription today within the authorised indications. A Swedish pharmacy can dispense it. The patient pays the list price, and the amount spent does not count towards the high-cost ceiling.

The evidence Swedish prescribers are working from

The weight-management authorisation rests largely on SURMOUNT-1, which randomised 2,539 adults with obesity and without diabetes and reported mean body-weight reductions at 72 weeks of 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo^[9]. The head-to-head comparison that drives a lot of Swedish clinic conversation is SURMOUNT-5, which randomised 751 adults with obesity and without diabetes and reported a mean reduction of 20.2% on tirzepatide versus 13.7% on semaglutide at 72 weeks (P less than 0.001)^[10].

Those are trial numbers, not promises. The tirzepatide safety profile carries the class contraindications, including personal or family history of medullary thyroid carcinoma and MEN-2 syndrome, and the dominant adverse events across the programme are gastrointestinal and dose-dependent. Whether tirzepatide is appropriate for any individual is a question for a Swedish clinician with the patient's history in front of them, not something a price list or a trial average settles.

What we do not yet know about Sweden

Three things are genuinely open. First, the TLV outcome on Mounjaro. A rejection would leave Sweden with no subsidised weight-management pharmacotherapy in this class; an approval with tight restrictions would be a reversal of the position the agency took on Wegovy in February 2026, and would raise immediate questions about equal treatment of the two products.

Second, whether a negotiated route reopens. TLV rejected Wegovy partly because tripartite price talks failed and because no follow-up mechanism existed to confirm that prescribing stayed inside the intended group^[7]. Both are solvable problems in principle. A volume-capped or outcome-linked agreement is the obvious shape of any future submission, for either manufacturer.

Third, the paediatric picture. The CHMP extension covers type-2 diabetes in children aged 10 and over, not obesity, and TLV has already signalled scepticism about paying for weight-management pharmacotherapy in adolescents. Those are separate questions that Swedish policy has not yet answered together.

Where this lands for Swedish readers

Tirzepatide is legal and available on prescription in Sweden for adult type-2 diabetes and adult weight management, under an EU authorisation that Sweden applies directly. It is not in the high-cost protection scheme, so the cost falls on the patient. Anything sold as tirzepatide outside a licensed Swedish or EU pharmacy sits outside that framework entirely and carries no assurance of identity, purity or dose. For the cross-country comparison, see tirzepatide regulation by country and the Sweden regulation hub.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Tirzepatide is a prescription-only medicine in Sweden. Always consult a qualified healthcare professional before using any prescription medicine. PeptideMethods.com does not sell, distribute, or facilitate the sale of any medicine or peptide product.

Regulatory disclaimer: This page reflects our understanding of the regulatory and reimbursement position as of July 2026. Regulations and TLV decisions change. Verify with Läkemedelsverket and TLV before making any decision. PeptideMethods.com is not a law firm and does not provide legal advice.